Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Dev Cell ; 48(3): 329-344.e5, 2019 02 11.
Article in English | MEDLINE | ID: mdl-30595538

ABSTRACT

Frequent SPOP mutation defines the molecular feature underlying one of seven sub-types of human prostate cancer (PrCa). However, it remains largely elusive how SPOP functions as a tumor suppressor in PrCa. Here, we report that SPOP suppresses stem cell traits of both embryonic stem cells and PrCa cells through promoting Nanog poly-ubiquitination and subsequent degradation. Mechanistically, Nanog, but not other pluripotency-determining factors including Oct4, Sox2, and Klf4, specifically interacts with SPOP via a conservative degron motif. Importantly, cancer-derived mutations in SPOP or at the Nanog-degron (S68Y) disrupt SPOP-mediated destruction of Nanog, leading to elevated cancer stem cell traits and PrCa progression. Notably, we identify the Pin1 oncoprotein as an upstream Nanog regulator that impairs its recognition by SPOP and thereby stabilizes Nanog. Thus, Pin1 inhibitors promote SPOP-mediated destruction of Nanog, which provides the molecular insight and rationale to use Pin1 inhibitor(s) for targeted therapies of PrCa patients with wild-type SPOP.


Subject(s)
Cell Proliferation/physiology , Nuclear Proteins/metabolism , Prostatic Neoplasms/metabolism , Repressor Proteins/metabolism , Stem Cells/cytology , Cullin Proteins/metabolism , Disease Progression , Humans , Kruppel-Like Factor 4 , Male , Mutation/genetics , Nuclear Proteins/genetics , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Protein Interaction Domains and Motifs/genetics , Repressor Proteins/genetics , Ubiquitination
SELECTION OF CITATIONS
SEARCH DETAIL